Aurora Cannabis (ACB) Long-Term Investments (2018 - 2026)

Aurora Cannabis (ACB) posted quarterly Long-Term Investments of $8.8 million for Q1 2026, up 866.91% quarter-over-quarter from $913511.6 in Q4 2022.

Aurora Cannabis (ACB) Long-Term Investments (2018 - 2026) Analysis & Trends

Aurora Cannabis (ACB) has reported Long-Term Investments for 6 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.

In Q1 2026, Long-Term Investments changed N/A year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (changed N/A YoY), while the FY2026 annual figure was $8.8 million, changed N/A from the prior year.
Long-Term Investments climbed to $8.8 million in Q1 2026 per ACB's latest filing, from $913511.6 in the prior quarter.
Across five years, Long-Term Investments topped out at $8.8 million in Q1 2026 and bottomed at $913511.6 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	92.58 Mn
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	63.23 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	1.14 Bn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	149.10 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	60.00 Mn
10	Aurora Cannabis	243.01 Mn	170.70 Mn	25.75 Mn	9.06 Mn

Download Data